๐ต๏ธ Pyxis Oncology, Inc. ($PYXS)
SEC insider & ownership activity, last 12 months ยท CIK 1782223 ยท every row links its SEC filing
Insider sell value was withheld pending verification over the last 12 months. No red-flag 8-Ks in the window.
Insider flow
0 buyers, $0 (0 lots) ยท 2 sellers, value withheld pending verification (4 lots)
| Insider | Buys | Bought | Sells | Sold | Last |
|---|---|---|---|---|---|
| Humphrey Rachel | 0 | โ | 3 | value withheld pending verification | Apr 21, 2025 |
| Dupont Jakob | 0 | โ | 1 | value withheld pending verification | Jun 30, 2026 |
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| GordonMD Global Investments LP | 12.1% | 13G | Jul 2, 2026 | filing โ | |
| GordonMD LONG Biased Master Fund LP | 12.1% | 13G | Jul 2, 2026 | filing โ | |
| GordonMD LONG Biased GP LLC | 12.1% | 13G | Jul 2, 2026 | filing โ | |
| Craig D. Gordon | 12.1% | 13G | Jul 2, 2026 | filing โ | |
| LARA Sullivan, M.D. | 11.2% | 13D | Mar 31, 2025 | filing โ | |
| Lara Sullivan | 10.3% | 13D | Dec 23, 2024 | filing โ | |
| BVF Partners L P/IL | 10.0% | 13G | Jul 10, 2026 | filing โ | |
| BVF INC/IL | 10.0% | 13G | Jul 10, 2026 | filing โ | |
| Mark N. Lampert | 10.0% | 13G | Jul 10, 2026 | filing โ | |
| BVF GP Holdings LLC | 9.2% | 13G | Jul 10, 2026 | filing โ | |
| Laurion Capital Management LP | 7.7% | 13G | Feb 9, 2026 | filing โ | |
| Benjamin Alexander Smith | 7.7% | 13G | Feb 9, 2026 | filing โ | |
| Janaka Sheehan Maduraperuma | 7.7% | 13G | Feb 9, 2026 | filing โ | |
| Biotechnology Value Fund L P | 5.5% | 13G | Jul 10, 2026 | filing โ | |
| BVF I GP LLC | 5.5% | 13G | Jul 10, 2026 | filing โ |
Planned insider sales (Form 144)
| Seller | Planned | Approx. sale date | |
|---|---|---|---|
| Dupont Jakob | $107K | Jun 30, 2026 | filing โ |
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Reg FD disclosure (7.01) | Sep 9, 2026 | filing โ |
| Other events (8.01) | Sep 9, 2026 | filing โ |
| Financial Statements and Exhibits (9.01) | Sep 9, 2026 | filing โ |
| Officer/director changes (5.02) | Sep 3, 2026 | filing โ |
| Reg FD disclosure (7.01) | Sep 3, 2026 | filing โ |
| Financial Statements and Exhibits (9.01) | Sep 3, 2026 | filing โ |
| Earnings (2.02) | Aug 13, 2026 | filing โ |
| Material agreement (1.01) | Jun 30, 2026 | filing โ |
| Unregistered equity sale (3.02) | Jun 30, 2026 | filing โ |
| Reg FD disclosure (7.01) | Jun 30, 2026 | filing โ |
| Shareholder vote (5.07) | Jun 15, 2026 | filing โ |
| Earnings (2.02) | May 14, 2026 | filing โ |
| Earnings (2.02) | Mar 23, 2026 | filing โ |
| Reg FD disclosure (7.01) | Mar 23, 2026 | filing โ |
| Officer/director changes (5.02) | Feb 6, 2026 | filing โ |
| Financial Statements and Exhibits (9.01) | Feb 6, 2026 | filing โ |
| Reg FD disclosure (7.01) | Dec 18, 2025 | filing โ |
| Other events (8.01) | Dec 18, 2025 | filing โ |
| Earnings (2.02) | Nov 3, 2025 | filing โ |